Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate

E. Gönczöl, Klara Berencsi, Steve Pincus, V. Endrész, Claude Méric, Enzo Paoletti, Stanley A. Plotkin

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Successful vaccination against the human cytomegalovirus (HCMV) requires induction of both neutralizing antibody and cytotoxic T lymphocyte (CTL) responses. The HCMV glycoprotein B (gB, UL55) would be one of the most important immunogens to induce neutralizing antibodies. We tested the immunogenicity of an ALVAC (canarypox)-HCMV-gB (ALVAC-gB) recombinant in mice and guinea pigs in order to provide preclinical data for a phase I clinical trial of a HCMV vaccine candidate. ALVAC is an attenuated vaccine strain of canarypox virus which replicates productively in avian species but abortively in mammalian cells. The ALVAC-gB recombinant inoculated subcutaneously in mice and intramuscularly in guinea pigs induced HCMV-specific neutralizing antibodies and gB-specific CTL responses. Ultraviolet irradiation of the ALVAC-gB recombinant before immunization diminished CTL responses, indicating that intracellular expression and processing of gB-protein were necessary for CTL induction. Prior immunity to vaccinia virus did not decrease immunogenicity of the ALVAC-gB recombinant in mice. Thus, despite its host range restriction, ALVAC-gB is potentially capable of inducing both humoral and cell-mediated immune responses to HCMV in both vaccinia-immune and non-immune individuals.

Original languageEnglish
Pages (from-to)1080-1085
Number of pages6
JournalVaccine
Volume13
Issue number12
DOIs
Publication statusPublished - 1995

Fingerprint

Human herpesvirus 5
glycoproteins
cytotoxic T-lymphocytes
Vaccines
Cytotoxic T-Lymphocytes
vaccines
Cytomegalovirus
Neutralizing Antibodies
neutralizing antibodies
guinea pigs
Canarypox virus
Cytomegalovirus Vaccines
mice
Guinea Pigs
immune response
Vaccinia
Attenuated Vaccines
Vaccinia virus
Clinical Trials, Phase I
Vaccinium

Keywords

  • Canarypox-gB recombinant
  • HCMV-gB-specific CTL
  • neutralizing antibody

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Immunology
  • Microbiology
  • Virology

Cite this

Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. / Gönczöl, E.; Berencsi, Klara; Pincus, Steve; Endrész, V.; Méric, Claude; Paoletti, Enzo; Plotkin, Stanley A.

In: Vaccine, Vol. 13, No. 12, 1995, p. 1080-1085.

Research output: Contribution to journalArticle

Gönczöl, E. ; Berencsi, Klara ; Pincus, Steve ; Endrész, V. ; Méric, Claude ; Paoletti, Enzo ; Plotkin, Stanley A. / Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. In: Vaccine. 1995 ; Vol. 13, No. 12. pp. 1080-1085.
@article{9ac2da459e4246bd878ba32b7121ccb7,
title = "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate",
abstract = "Successful vaccination against the human cytomegalovirus (HCMV) requires induction of both neutralizing antibody and cytotoxic T lymphocyte (CTL) responses. The HCMV glycoprotein B (gB, UL55) would be one of the most important immunogens to induce neutralizing antibodies. We tested the immunogenicity of an ALVAC (canarypox)-HCMV-gB (ALVAC-gB) recombinant in mice and guinea pigs in order to provide preclinical data for a phase I clinical trial of a HCMV vaccine candidate. ALVAC is an attenuated vaccine strain of canarypox virus which replicates productively in avian species but abortively in mammalian cells. The ALVAC-gB recombinant inoculated subcutaneously in mice and intramuscularly in guinea pigs induced HCMV-specific neutralizing antibodies and gB-specific CTL responses. Ultraviolet irradiation of the ALVAC-gB recombinant before immunization diminished CTL responses, indicating that intracellular expression and processing of gB-protein were necessary for CTL induction. Prior immunity to vaccinia virus did not decrease immunogenicity of the ALVAC-gB recombinant in mice. Thus, despite its host range restriction, ALVAC-gB is potentially capable of inducing both humoral and cell-mediated immune responses to HCMV in both vaccinia-immune and non-immune individuals.",
keywords = "Canarypox-gB recombinant, HCMV-gB-specific CTL, neutralizing antibody",
author = "E. G{\"o}ncz{\"o}l and Klara Berencsi and Steve Pincus and V. Endr{\'e}sz and Claude M{\'e}ric and Enzo Paoletti and Plotkin, {Stanley A.}",
year = "1995",
doi = "10.1016/0264-410X(95)00048-6",
language = "English",
volume = "13",
pages = "1080--1085",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate

AU - Gönczöl, E.

AU - Berencsi, Klara

AU - Pincus, Steve

AU - Endrész, V.

AU - Méric, Claude

AU - Paoletti, Enzo

AU - Plotkin, Stanley A.

PY - 1995

Y1 - 1995

N2 - Successful vaccination against the human cytomegalovirus (HCMV) requires induction of both neutralizing antibody and cytotoxic T lymphocyte (CTL) responses. The HCMV glycoprotein B (gB, UL55) would be one of the most important immunogens to induce neutralizing antibodies. We tested the immunogenicity of an ALVAC (canarypox)-HCMV-gB (ALVAC-gB) recombinant in mice and guinea pigs in order to provide preclinical data for a phase I clinical trial of a HCMV vaccine candidate. ALVAC is an attenuated vaccine strain of canarypox virus which replicates productively in avian species but abortively in mammalian cells. The ALVAC-gB recombinant inoculated subcutaneously in mice and intramuscularly in guinea pigs induced HCMV-specific neutralizing antibodies and gB-specific CTL responses. Ultraviolet irradiation of the ALVAC-gB recombinant before immunization diminished CTL responses, indicating that intracellular expression and processing of gB-protein were necessary for CTL induction. Prior immunity to vaccinia virus did not decrease immunogenicity of the ALVAC-gB recombinant in mice. Thus, despite its host range restriction, ALVAC-gB is potentially capable of inducing both humoral and cell-mediated immune responses to HCMV in both vaccinia-immune and non-immune individuals.

AB - Successful vaccination against the human cytomegalovirus (HCMV) requires induction of both neutralizing antibody and cytotoxic T lymphocyte (CTL) responses. The HCMV glycoprotein B (gB, UL55) would be one of the most important immunogens to induce neutralizing antibodies. We tested the immunogenicity of an ALVAC (canarypox)-HCMV-gB (ALVAC-gB) recombinant in mice and guinea pigs in order to provide preclinical data for a phase I clinical trial of a HCMV vaccine candidate. ALVAC is an attenuated vaccine strain of canarypox virus which replicates productively in avian species but abortively in mammalian cells. The ALVAC-gB recombinant inoculated subcutaneously in mice and intramuscularly in guinea pigs induced HCMV-specific neutralizing antibodies and gB-specific CTL responses. Ultraviolet irradiation of the ALVAC-gB recombinant before immunization diminished CTL responses, indicating that intracellular expression and processing of gB-protein were necessary for CTL induction. Prior immunity to vaccinia virus did not decrease immunogenicity of the ALVAC-gB recombinant in mice. Thus, despite its host range restriction, ALVAC-gB is potentially capable of inducing both humoral and cell-mediated immune responses to HCMV in both vaccinia-immune and non-immune individuals.

KW - Canarypox-gB recombinant

KW - HCMV-gB-specific CTL

KW - neutralizing antibody

UR - http://www.scopus.com/inward/record.url?scp=0029142653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029142653&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(95)00048-6

DO - 10.1016/0264-410X(95)00048-6

M3 - Article

VL - 13

SP - 1080

EP - 1085

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12

ER -